Signaturefd LLC Boosts Stake in Merck & Co., Inc. $MRK

Signaturefd LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 51,409 shares of the company’s stock after purchasing an additional 4,644 shares during the period. Signaturefd LLC’s holdings in Merck & Co., Inc. were worth $5,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of MRK. Darwin Wealth Management LLC raised its holdings in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after buying an additional 216 shares during the period. Barnes Dennig Private Wealth Management LLC boosted its holdings in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after acquiring an additional 266 shares during the period. Evolution Wealth Management Inc. purchased a new position in Merck & Co., Inc. during the 2nd quarter valued at $31,000. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at $31,000. Finally, Wealth Watch Advisors INC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In related news, CEO Robert M. Davis sold 47,434 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the sale, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. This represents a 9.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. UBS Group upped their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a research note on Thursday, January 8th. Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $100.00 to $102.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Finally, BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $82.00 to $130.00 in a research report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $127.13.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $120.62 on Friday. The company has a market cap of $298.21 billion, a PE ratio of 16.57, a P/E/G ratio of 2.44 and a beta of 0.26. The firm’s 50 day moving average price is $117.72 and its 200-day moving average price is $103.23. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. Merck & Co., Inc.’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.